WallStSmart
TRDA

Entrada Therapeutics Inc

NASDAQ: TRDA · HEALTHCARE · BIOTECHNOLOGY

$14.50
+7.41% today

Updated 2026-05-01

Market cap
$503.12M
P/E ratio
P/S ratio
19.79x
EPS (TTM)
$-3.47
Dividend yield
52W range
$5 – $14
Volume
0.2M

WallStSmart proprietary scores

28
out of 100
Grade: F
Strong Sell
Investment rating
3.3
Growth
D
8.0
Quality
A
2.5
Profitability
F
5.0
Valuation
C+
2/9
Piotroski F-Score
Weak
2.4
Altman Z-Score
Grey zone
Industry rank
View all highly rated stocks (75+) →204 stocks currently score above 75

Price targets

Analyst target
$21.40
+47.59%
12-Month target
Intrinsic (DCF)
Margin of safety
0 Strong Buy7 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths
+ Debt/equity 0.15x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-32.41M
- Revenue declining -96.50% QoQ

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$25.26M$129.01M$210.78M$25.42M$25.42M
Net income$-87.46M$-6.68M$65.63M$-143.75M$-39.16M
EPS$-3.47
Free cash flow$-96.67M$134.19M$-44.72M$-129.55M$-32.41M
Profit margin-346.23%-5.18%31.13%-565.48%

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
TRDA$503.12M283.32.55.08.0Avoid
LLY$760.43B7810.010.05.06.5Strong Buy
JNJ$547.28B594.79.03.36.0-41.61%Buy
ABBV$360.63B634.08.04.75.0-26.29%Buy
UNH$336.47B545.35.57.34.8+42.35%Buy
AZN$287.11B646.78.05.35.0+4.07%Buy

Smart narrative

Entrada Therapeutics Inc trades at $14.50. Our Smart Value Score of 28/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 2.36, it sits in the grey zone. TTM revenue stands at $25.42M.

Frequently asked questions

What is Entrada Therapeutics Inc's stock price?
Entrada Therapeutics Inc (TRDA) trades at $14.50.
Is Entrada Therapeutics Inc overvalued?
Smart Value Score 28/100 (Grade F, Strong Sell).
What is the price target of Entrada Therapeutics Inc (TRDA)?
The analyst target price is $21.40, representing +47.6% upside from the current price of $14.50.
What is Entrada Therapeutics Inc's revenue?
TTM revenue is $25.42M.
Piotroski F-Score?
2/9 — weak financial health.
Altman Z-Score?
2.36 — grey zone.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio19.79x
ROE-39.10%
Beta-0.15
50D MA$12.57
200D MA$9.03
Shares out0.04B
Float0.02B
Short ratio
Avg volume0.2M

Performance

1 week+6.89%
1 month+0.15%
3 months+18.01%
YTD+31.32%
1 year
3 years
5 years